An observational study in Cervical Neuroendocrine Carcinoma, sponsored by Peking Union Medical College Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Peking Union Medical College Hospital · Observational
This retrospective study reviews existing medical records. No new treatments or tests are given. The study asks how well immunotherapy worked for people with a rare cancer called neuroendocrine carcinoma of the cervix. Immunotherapy is a treatment that helps the body's immune system fight cancer. The investigators will review the records of approximately 150 participants treated with immunotherapy for this cancer. The study will evaluate: (1) how long participants lived without the cancer getting worse; (2) how long participants lived overall; (3) whether the cancer shrank or stopped growing; (4) what side effects occurred, especially immune-related side effects; and (5) whether certain tumor markers or different treatment plans made a difference. Participants will not be contacted or asked to complete any procedures. Only information already contained in medical records will be used. Names and other personal details will be removed to protect privacy. The study has been approved by the ethics committee at Peking Union Medical College Hospital. The results may help doctors choose the best treatment for patients with this rare cancer. Results will be shared in medical journals and at medical meetings. For patients and families: This study does not enroll new participants. Questions about this cancer or immunotherapy should be directed to a physician.
172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 66 are open to participants now.
This study's planned enrollment of 150 is above the median of 90 across 24 observational studies indexed under Carcinoma, Neuroendocrine.
Browse Carcinoma, Neuroendocrine studies →Peking Union Medical College Hospital is the lead sponsor of 1,155 studies on the registry; 475 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will be selected from patients diagnosed with neuroendocrine carcinoma of the cervix who received PD-1/PD-L1 inhibitor-based immunotherapy at Peking Union Medical College Hospital between January 2020 and December 2026. Eligible participants will be identified through retrospective review of medical records. Inclusion criteria include: age ≥18 years; histologically confirmed cervical neuroendocrine carcinoma (small cell, large cell, or mixed type); received at least one cycle of PD-1/PD-L1 inhibitor-based immunotherapy; and availability of complete clinical records including baseline characteristics, treatment regimen, efficacy assessment, and survival follow-up. Patients with severely incomplete key clinical data or those who participated in other interventional clinical trials that may affect efficacy or survival assessment will be excluded. A total of approximately 150 eligible patients will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥ 18 years at the time of diagnosis;
Histopathologically confirmed diagnosis of neuroendocrine carcinoma of the cervix (NECC), including small cell type, large cell type, and mixed type;
Received at least one cycle of -based therapy targeting the PD-1/PD-L1 pathway;
Complete medical records, detailed treatment regimens, and available efficacy evaluation data;
Exclusion Criteria:
Did not meet all of the above inclusion criteria;
Key clinical data severely missing, making it impossible to extract valid informationinformation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: No study intervention; observational study.
The exposure was PD-1/PD-L1 inhibitor-based immunotherapy, including monotherapy or combination with chemotherapy and/or anti-angiogenic agents. Treatment was given as routine clinical care, not assigned by the study.
Progression-free survival
Time frame: From the date of initiation of immunotherapy to the date of first documented disease progression or the date of death from any cause, whichever occurs first, assessed up to 60 months; participants alive and without documented progression will be censored
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking Union Medical College Hospital →